Hassan Ramadan, MD
Pediatric Otolaryngology · Morgantown, WVNPI 1538263009
Payments from drug & device makers
What this record shows
6 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 57.0% of the total. Reporting peaked in 2021 at $3,025 and has fallen 71.3% since, to $869 in 2025.
Across 26 payments — averaging $204.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Aerin Medical Inc.$1K
- Integra Lifesciences Corporation$519
- Stryker$485
- Sanofi$82
- Inspire Medical Systems, Inc.$49
Across 9 payments — averaging $2446.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$16K
- Optinose US, Inc.$4K
- Roche Products Limited$3K
What the payments were for
- Consulting fees$3,02557%
- Food & beverage$2,28043%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $3,025 |
| Aerin Medical Inc. | 11 | $1,146 |
| Integra Lifesciences Corporation | 3 | $519 |
| Stryker | 8 | $485 |
| Sanofi | 1 | $82 |
| Inspire Medical Systems, Inc. | 2 | $49 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVAER STYLUS$829
- RHINAER STYLUS$829
- Acclarent Aera$519
- Inspira Air$519
- RELIEVA SPINPLUS NAV$519
- TruDi Probe$519
- XPRESS ENT DILATION SYSTEM$168
- SCOPIS ENT$159
How this compares
Too few pediatric otolaryngology providers in West Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 25 | $93,394 |
| Dupixent SyringeDupilumab | 11 | $39,840 |
| Cefdinir | 30 | $651 |
| Ipratropium Bromide | 14 | $457 |
| Fluticasone Propionate | 33 | $359 |
| Mupirocin | 17 | $264 |
| Montelukast Sodium | 11 | $227 |
| Prednisone | 11 | $25 |
Paid to pharmacies, not to this prescriber.
Other pediatric otolaryngology in Morgantown
- Hussein JaffalMorgantown$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.